Attorney's Docket No. 033126-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Patent Application of

Anticony E. Bolton et al.

(\$57ication No.: 09/866,569

Filed: May 25, 2001

For: APOPTOTIC ENTITIES FOR USE IN TREATMENT OF ENDOTHELIUM

DYSFUNCTION DISORDERS

Group Art Unit: 1614

Examiner: Unassigned

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

1	$[\mathbf{x}]$	NI.	additional	faa faa	submission	of on	IDC:	
	X	เทก	addillonai	ree for	SHDIBISSION	oi an	1135 18	reamrea.
- 1	4	1,0	additional	100 101	Cacillioololl	O1 W11	120	. oqui. ou.

- [] The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- [] A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- [] Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.


P.O. Box 1404 Alexandria, Virginia 22313-1404

(650) 622-2300

Date: September 21, 2001

Leslie J. Boley

Registration No. 41,490



INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

Publications

Bombeli, T., et al., Apoptotic Vascular Endothelial Cells Become Procoagulant," *Blood*, **89:**2429-2442 (1997).

Buttke and Sandstrom, et al., "Oxidative Stress As a Mediator of Apoptosis," *Immunology Today*, **15:**7-10 (1994).

De Caterina, R., "Endothelial dysfunctions: common denominators in vascular disease," *Current Opinions in Lipidology*, **11:**9-23, (2000).

Information Disclosure Statement Application No. <u>09/866,569</u> Attorney's Docket No. <u>033136-185</u> Page 2

Fadok, V.A., et al., "Exposure of Phosphatidylserine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and Removal by Macrophages," *Journal of Immunology*, **148**:2207-2216 (1992).

Fadok, V.A. et al., "A receptor for phosphatidylserine-specific clearance of apoptotic cells," *Nature*, **405**:85-90 (2000).

Gavrieli, Y., et al., "Identification of Programmed Cell Death In Situ via Specific Labelling of Nuclear DNA Fragmentation," *J. of Cell Biology*, **119:**493-501 (1992).

Guijarro, C., et al., "3-Hydrxy-3 Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle in Culture," *Circulation Research*, **83:**490-500 (1998).

Kerr et al., "Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics," *British Journal of Cancer*, **26**:239-257 (1991).

Kondo, et al., "Lymphocyte Function-Associated Antigen-1 is Required for Maximum Elicitation of Allergic Contact Dermatitis," *Br. J. Dermatol*. **131:**354-359 (1994).

Kondo, et al., "Interleukin-10 Inhibits the Elicitation Phase of Allergic Contact Hypersensitivity," *The Journal of Investigative Dermatology*, **103:**811-814 (1994).

Libby, P., "Changing concepts of atherogenesis," *Journal of Internal Medicine*, **247**:349-358, (2000).

Information Disclosure Statement Application No. <u>09/866,569</u> Attorney's Docket No. <u>033136-185</u> Page 3

Loo, D. T. and Rillema, J.R., "Measurement of Cell Death," *Methods in Cell Biology*, 57:251-264 (1998).

Salvioli, S., et al., "JC-1, but not DiOC₆(3) or Rhodamine 123, is a Reliable Fluorescent Probe to Assess $\Delta\Psi$ Changes in Intact Cells: Implications For Studies on Mitochondrial Functionality During Apoptosis," *FEBS Letters* 411:77-82 (1997).

Susin, S.A., "Mitochondrial Release of Caspase-2 and -9 During the Apoptotic Process," *Journal of Experimental Medicine*, **189:**381-394 (1994).

Suzuki, Y., "Cell Death Phagocytosis, and Neurogenesis in Mouse Olfactory Epithelium and Vomeronasal Organ After Colcicine Treatment," *Annals of the New York Academy of Sciences*, **855**:252-254 (1998).

Teiger, E., "Apoptosis in Pressure Overload-Induced Heart Hypertrophy in the Rat," *Journal of Clinical Investigation*, **97:**2891-2897 (1996).

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b)

Information Disclosure Statement Application No. <u>09/866,569</u> Attorney's Docket No. <u>033136-185</u> Page 4

To assist the Examiner, the listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Lestie I Boley

Registration No. 41,490

P.O. Box 1404 Alexandria, Virginia 22313-1404 (650) 622-2300

Date: September 21, 2001